Fujifilm Diosynth Biotechnologies and ContraFect Corp. have signed a contract to support the process development and cGMP manufacture of CF-301, ContraFect’s Staphylococcal-specific bacteriophage lysin. CF-301 is ContraFect’s lead compound with potent activity against all forms of Staph infections, including methicillin-resistant (MRSA) and vancomycin-resistant strains (VISA/VRSA).   Fujifilm Diosynth will use its pAVEway advanced protein expression technology to establish a high productivit...